Drug Trial Radar · NCT07140900
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 7, 2025
Primary completion
Oct 27, 2027
Study completion Oct 29, 2029
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the trial is to evaluate the safety and tolerability of xaluritamig in combination with darolutamide or abiraterone.
Conditions
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
XaluritamigDrug
Participants will receive xaluritamig intravenously.
DarolutamideDrug
Participants will receive darolutamide orally.
AbirateroneDrug
Participants will receive abiraterone orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to approximately 2.5 years
- Number of Participants with Treatment-related Adverse EventsTime frame: Up to approximately 2.5 years
- Number of Participants with Clinically Significant Changes in Vital SignsTime frame: Up to approximately 2.5 years
- Number of Participants with Clinically Significant Changes in Clinical Laboratory TestsTime frame: Up to approximately 2.5 years
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Dana Farber Cancer Institute
Boston, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Cleveland Clinic Foundation
Cleveland, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Hillman Cancer Center
Pittsburgh, Pennsylvania
South Texas Accelerated Research Therapeutics - Carolinas
Myrtle Beach, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia
Cabrini Hospital
Clayton, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Kantonsspital Graubuenden
Chur, Switzerland
Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland
Kantonsspital Sankt Gallen
Sankt Gallen, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.